Alimera Sciences Inc

Alimera Sciences — Q2 2017 Earnings Presentation

12 slides from Alimera Sciences's earnings presentation, Aug 3, 2017

  1. Slide 1: Second Quarter 2017 Results Conference Call

    Second Quarter 2017 Results Conference Call Thursday, August 3, 2017 Exhibit 99.2

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains ““forward-looking statements,”“ within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the opportunity for further growth in 2017 for ILUVIEN and the ability of Alimera to achieve positive operating

  3. Slide 3: 2Q 2017 Highlights

    3 2Q 2017 Highlights Revenue Growth 2Q17 $10.4M 2Q16 $9.6M 8% • Positive Adjusted EBITDA* of $0.5 million Q2 2017 • 8% Global revenue growth Q2 2017 over Q2 2016 • Global End User Demand increased 6% Q2 2017 compared to Q2 2016 • ILUVIEN launched in Italy by our Italian distributor in June © 2017 Al

  4. Slide 4: Positive Adjusted EBITDA of $0.5M Achieved

    4 Positive Adjusted EBITDA* of $0.5M Achieved © 2017 Alimera Sciences, Inc., All Rights Reserved Achieved due to Cost saving measures Increases in end user demand and revenue • Management of operating expenses • Increases in end user demand • Revenue growth *Please see Non-GAAP financial information

  5. Slide 5: Uveitis Indication for ILUVIEN

    5 Uveitis Indication for ILUVIEN © 2017 Alimera Sciences, Inc., All Rights Reserved July 2017 Licensed Territories for Posterior Uveitis • Europe • Middle East • Africa Planned submission for uveitis in 17 EU countries (where ILUVIEN is currently approved for DME) in Q1 2018 Announced transaction th

  6. Slide 6: Positive Real World Data

    6 Positive Real World Data © 2017 Alimera Sciences, Inc., All Rights Reserved Medisoft Audit 305 patients 345 eyes United Kingdom Published in EYE, July 2017 USER Study 130 patients 160 eyes U.S. To be Presented Fall 2017, Multiple Venues

  7. Slide 7: Financial Overview

    Financial Overview Rick Eiswirth, President & CFO

  8. Slide 8: Global, U.S. and International Revenue

    © 2017 Alimera Sciences, All Rights Reserved 8 2Q17 $10.4M 2Q16 $9.6M 8% Global Revenue U.S. End User Unit Demand 2Q17 $8.1M 2Q16 $7.2M U.S. Revenue 2Q16 2Q17 $2.3M $2.3M International Revenue 13% 9%

  9. Slide 9: Operating Expenses, Net Loss and Adjusted EBITDA

    9 © 2017 Alimera Sciences, Inc., All Rights Reserved 2Q16 2Q17 $11.0M $15.5M 29% Operating Expenses 2Q16 2Q17 $2.8M $6.9M 59% GAAP Net Loss 2Q16 2Q17 $0.5M ($4.4M) Adj. EBITDA* 2Q16 2Q17 $9.1M $13.4M 32% Adj. Operating Expenses* *Please see Non-GAAP financial information on slide 11 of this presenta

  10. Slide 10: Closing Remarks

    Closing Remarks Dan Myers, CEO

  11. Slide 11: Non-GAAP Financial Information

    11 Non-GAAP Financial Information © 2017 Alimera Sciences, Inc., All Rights Reserved Alimera believes that the non-GAAP financial information provided in this presentation can assist investors in the overall understanding of its financial performance when considered together with GAAP figures. This

  12. Slide 12: Second Quarter 2017 Results Conference Call

    Second Quarter 2017 Results Conference Call Thursday, August 3, 2017

Alimera Sciences — Q2 2017 Earnings Presentation on 6ix